"text","id","sectionNumber","sectionTitle","name","uuid:ID"
"","NarrativeContent_1","0","Root","ROOT","ac372215-2cab-4e8b-ac78-1e68d1e372ec"
"<div><usdm:ref klass=""StudyIdentifier"" id=""StudyIdentifier_1"" attribute=""studyIdentifier""/></div>","NarrativeContent_2","1","PROTOCOL SUMMARY","SECTION 1","28d90c86-7a8e-4dcd-a6e2-3618a5a596f1"
"<div></div>","NarrativeContent_3","1.1","Protocol Synopsis","SECTION 1.1","b9c6bf3b-4608-44e9-a5c6-36485ba78ebb"
"<div></div>","NarrativeContent_4","1.2","Trial Schema","SECTION 1.2","fc393061-40ae-4567-890e-245366de9cd1"
"<div></div>","NarrativeContent_5","1.3","Schedule of Activities","SECTION 1.3","cc8bdb6d-5a40-46de-a633-f8ae0cd64423"
"<div></div>","NarrativeContent_6","2","INTRODUCTION","SECTION 2","866e7279-a8d9-4cac-867a-8c2324a3e788"
"<div></div>","NarrativeContent_7","2.1","Purpose of Trial","SECTION 2.1","01d1b075-3b34-4ca3-bd26-30d646b6ce93"
"<div></div>","NarrativeContent_8","2.2","Summary of Benefits and Risks","SECTION 2.2","0a71f80b-fcd5-4411-9dee-e3a70ce1232b"
"<div></div>","NarrativeContent_9","3","TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS","SECTION 3","5066a594-325e-4690-b8a7-002cdd5684f2"
"<div><table>
  <tr>
    <th style=""vertical-align: top"">Primary Objective</th>
    <th style=""vertical-align: top"">Primary Endpoint</th>
  </tr>
  <tr>
    <td style=""vertical-align: top""><usdm:ref klass=""Objective"" namexref=""OBJ1"" attribute=""description""/></td>
    <td style=""vertical-align: top""><usdm:ref klass=""Endpoint"" id=""Endpoint_1"" attribute=""description""/></td>
  </tr>
</table></div>","NarrativeContent_10","3.1","Primary Objectives","SECTION 3.1","11e720d3-b758-4d4e-9e08-221045c5166b"
"<div></div>","NarrativeContent_11","4","TRIAL DESIGN","SECTION 4","3b6a317a-d5a1-4a12-8bf5-6b6d49c861a2"
"<div></div>","NarrativeContent_12","4.1","Description of Trial Design","SECTION 4.1","1579ef49-a9aa-44a7-831b-24c8cdd4032d"
"<div></div>","NarrativeContent_13","4.1.1","Participant Input into Design","SECTION 4.1.1","ff878aad-faf4-4c9f-ba42-8a17b926481f"
"<div></div>","NarrativeContent_14","4.2","Rationale for Trial Design","SECTION 4.2","cca13e57-4838-4ea1-bdf3-bf6c0f24096c"
"<div></div>","NarrativeContent_15","4.2.1","Rationale for Comparator","SECTION 4.2.1","f150035a-55af-405d-a9f4-0f9dc5e3f609"
"<div></div>","NarrativeContent_16","4.2.2","Rationale for Adaptive or Novel Trial Design","SECTION 4.2.2","864911cd-f239-4131-84f2-c3f7c571084e"
"<div></div>","NarrativeContent_17","4.2.3","Other Trial Design Considerations","SECTION 4.2.3","5090f978-682c-449c-8380-c8ceb4218455"
"<div></div>","NarrativeContent_18","4.3","Access to Trial Intervention After End of Trial","SECTION 4.3","6de4ee2a-8734-492e-bc11-28be69577569"
"<div></div>","NarrativeContent_19","4.4","Start of Trial and End of Trial","SECTION 4.4","0ad01339-7186-46c5-b7b0-2ee7887e644a"
"<div></div>","NarrativeContent_20","5","TRIAL POPULATION","SECTION 5","883fa7fb-58b2-4fc4-9e00-aa700ca86d7a"
"<div></div>","NarrativeContent_21","5.1","Selection of Trial Population","SECTION 5.1","08398837-3dd5-4ee1-a571-cd1235b0a3cd"
"<div></div>","NarrativeContent_22","5.2","Rationale for Trial Population","SECTION 5.2","8fbad7e3-d53a-4d8d-97be-094c765e9e23"
"<div><p>Inclusion criteria are:</p>
<ul>
  <li>1. Something</li>
  <li>2. Something else</li>
</ul></div>","NarrativeContent_23","5.3","Inclusion Criteria","SECTION 5.3","47ca53d3-199f-4c6d-97ef-252a0e2f5488"
"<div><p>Exclusion criteria are:</p>
<ul>
  <li>1. Dont do this</li>
  <li>2. And don't do that</li>
</ul></div>","NarrativeContent_24","5.4","Exclusion Criteria","SECTION 5.4","0755c16b-a8b1-47b0-add1-31207b431fb3"
"<div></div>","NarrativeContent_25","5.5","Lifestyle Considerations","SECTION 5.5","1ef76b88-a8f2-40b1-a2ab-7e749e586828"
"<div></div>","NarrativeContent_26","5.5.1","Meals and Dietary Restrictions","SECTION 5.5.1","9f0bb1c2-0c87-42db-8106-e113febc4dad"
"<div></div>","NarrativeContent_27","5.5.2","Caffeine, Alcohol, Tobacco, and Other Habits","SECTION 5.5.2","687b4f16-1f06-4ac3-9a95-1d6e860b2d0a"
"<div></div>","NarrativeContent_28","5.5.3","Physical Activity","SECTION 5.5.3","05693410-db8b-4746-917a-a2799d4779bd"
"<div></div>","NarrativeContent_29","5.5.4","Other Activity","SECTION 5.5.4","03cfc5ca-2fe0-4d29-b41f-7f0a1645812b"
"<div></div>","NarrativeContent_30","5.6","Screen Failures","SECTION 5.6","0aae9ad1-de63-4fa3-a247-70499944cdef"
"<div></div>","NarrativeContent_31","6","TRIAL INTERVENTION AND CONCOMITANT THERAPY","SECTION 6","4599cf11-13c5-490c-a704-69e4b233a385"
"<div></div>","NarrativeContent_32","6.1","Description of Trial Intervention","SECTION 6.1","1ee64e38-80ed-46d7-815b-0f6919184762"
"<div></div>","NarrativeContent_33","6.2","Rationale for Trial Intervention","SECTION 6.2","abf916b3-51ce-462d-8301-d577bdad094e"
"<div></div>","NarrativeContent_34","6.3","Dosing and Administration","SECTION 6.3","8e72543b-79bd-44ea-a64a-5766ada5ec16"
"<div></div>","NarrativeContent_35","6.3.1","Trial Intervention Dose Modification","SECTION 6.3.1","b494297d-3701-4167-a8fe-9f58056c497b"
"<div></div>","NarrativeContent_36","6.4","Treatment of Overdose","SECTION 6.4","22a64732-65b7-47b8-aa70-424e9e0f0ed2"
"<div></div>","NarrativeContent_37","6.5","Preparation, Handling, Storage and Accountability","SECTION 6.5","fa3bb4f5-ca58-4928-9e97-88ce18739ad2"
"<div></div>","NarrativeContent_38","6.5.1","Preparation of Trial Intervention","SECTION 6.5.1","84c57eec-0c8d-4282-916a-b5a17c042a0e"
"<div></div>","NarrativeContent_39","6.5.2","Handling and Storage of Trial Intervention","SECTION 6.5.2","46fb3fff-5ead-4622-8b7d-b2a0225168f7"
"<div></div>","NarrativeContent_40","6.5.3","Accountability of Trial Intervention","SECTION 6.5.3","51350d00-b019-4e05-b85b-713e5e8b88e3"
"<div></div>","NarrativeContent_41","6.6","Participant Assignment, Randomisation and Blinding","SECTION 6.6","79eb4f13-9dab-49ef-ba2b-631c94bee1cd"
"<div></div>","NarrativeContent_42","6.6.1","Participant Assignment","SECTION 6.6.1","0367ad6d-b96b-46db-bf83-a2017bcef070"
"<div></div>","NarrativeContent_43","6.6.2","Randomisation","SECTION 6.6.2","10912d36-9906-410a-a52f-720e66d6dfc6"
"<div><p>Blinding and unblinding text here please</p></div>","NarrativeContent_44","6.6.3","Blinding and Unblinding","SECTION 6.6.3","5d5c9aae-d0e6-498e-83e3-9d23e8553b1c"
"<div></div>","NarrativeContent_45","6.7","Trial Intervention Compliance","SECTION 6.7","e8b67c32-9b4e-4742-bee7-9dd40540c43e"
"<div></div>","NarrativeContent_46","6.8","Concomitant Therapy","SECTION 6.8","a74900c3-d941-4d92-93b9-8a9fbbf46c2a"
"<div></div>","NarrativeContent_47","6.8.1","Prohibited Concomitant Therapy","SECTION 6.8.1","97872535-fe1a-4e3b-9d1c-a08843ab712f"
"<div></div>","NarrativeContent_48","6.8.2","Permitted Concomitant Therapy","SECTION 6.8.2","bd997d82-7c3f-4d34-961b-3913c25e897a"
"<div></div>","NarrativeContent_49","6.8.3","Rescue Therapy","SECTION 6.8.3","7e4443d5-475b-47c1-8c8c-487412b438a4"
"<div></div>","NarrativeContent_50","6.8.4","Other Therapy","SECTION 6.8.4","41660c32-d28e-4a9c-bfc5-5c615acec044"
"<div></div>","NarrativeContent_51","7","DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL","SECTION 7","d45405c5-89b2-43da-8a33-ee36f0dc3641"
"<div></div>","NarrativeContent_52","7.1","Discontinuation of Trial Intervention","SECTION 7.1","f42490d3-c9b3-4a98-b770-a278310f64c1"
"<div></div>","NarrativeContent_53","7.1.1","Criteria for Permanent Discontinuation of Trial Intervention","SECTION 7.1.1","9fe5aad5-9a37-4ae3-9ff2-8f5671fdc03e"
"<div></div>","NarrativeContent_54","7.1.2","Temporary Discontinuation or Interruption of Trial Intervention","SECTION 7.1.2","da82819b-1526-44ae-8df1-57f9051270f5"
"<div></div>","NarrativeContent_55","7.1.3","Rechallenge","SECTION 7.1.3","7492a2bf-bae2-4178-a3d7-d49c9d4324ff"
"<div></div>","NarrativeContent_56","7.2","Participant Withdrawal from the Trial","SECTION 7.2","7b6a5255-21b9-440e-bd05-7f6bb7158083"
"<div></div>","NarrativeContent_57","7.3","Lost to Follow-Up","SECTION 7.3","05ab7a35-ccaf-4739-bc34-946b6b0ac076"
"<div></div>","NarrativeContent_58","7.4","Trial Stopping Rules","SECTION 7.4","460efaa6-386e-41a1-a5b4-8e5694fc9b1f"
"<div></div>","NarrativeContent_59","8","TRIAL ASSESSMENTS AND PROCEDURES","SECTION 8","3564081e-fe0b-431f-881a-7c4d9329958d"
"<div></div>","NarrativeContent_60","8.1","Screening/Baseline Assessments and Procedures","SECTION 8.1","c93555ec-31ad-4c00-8101-9b490db4f63c"
"<div></div>","NarrativeContent_61","8.2","Efficacy Assessments and Procedures","SECTION 8.2","66322c72-6f54-46c1-a19c-b435ecfd7ef0"
"<div></div>","NarrativeContent_62","8.3","Safety Assessments and Procedures","SECTION 8.3","e4674483-08d9-4be8-9dbb-e22e0029097a"
"<div></div>","NarrativeContent_63","8.3.1","Physical Examination","SECTION 8.3.1","e0092042-26ca-4ec2-9cfa-4f85e7b94dae"
"<div></div>","NarrativeContent_64","8.3.2","Vital Signs","SECTION 8.3.2","802d58f5-13b1-4314-9efb-24c1c172097d"
"<div></div>","NarrativeContent_65","8.3.3","Electrocardiograms","SECTION 8.3.3","ae364449-41d7-4e15-9aaf-8205052bb774"
"<div></div>","NarrativeContent_66","8.3.4","Clinical Laboratory Assessments","SECTION 8.3.4","daafcd95-2de8-4073-b63e-d6f24a3c309e"
"<div></div>","NarrativeContent_67","8.3.5","Suicidal Ideation and Behaviour Risk Monitoring","SECTION 8.3.5","2dd6d453-a701-4b06-b43f-10a20f87178a"
"<div></div>","NarrativeContent_68","8.4","Adverse Events and Serious Adverse Events","SECTION 8.4","ed7cd6a0-99c2-4d0f-8bb4-7c7a2a0c85a5"
"<div></div>","NarrativeContent_69","8.4.1","Definitions of AE and SAE","SECTION 8.4.1","a539ab4b-f991-4096-bfed-a6b39003be86"
"<div></div>","NarrativeContent_70","8.4.2","Time Period and Frequency for Collecting AE and SAE Information","SECTION 8.4.2","1f710835-4768-4756-9415-bab8bf3b050c"
"<div></div>","NarrativeContent_71","8.4.3","Identifying AEs and SAEs","SECTION 8.4.3","8c508a2e-5c65-41fa-b820-ebb4a481e756"
"<div></div>","NarrativeContent_72","8.4.4","Recording of AEs and SAEs","SECTION 8.4.4","a58d6be3-9ab5-4fa6-8e17-db5b5c6217ec"
"<div></div>","NarrativeContent_73","8.4.5","Follow-up of AEs and SAEs","SECTION 8.4.5","2bc77e4b-ce15-4018-92d6-5bf16a4242b5"
"<div></div>","NarrativeContent_74","8.4.6","Reporting of SAEs","SECTION 8.4.6","af78acb7-40ec-4b57-8b54-7280131279de"
"<div></div>","NarrativeContent_75","8.4.7","Regulatory Reporting Requirements for SAEs","SECTION 8.4.7","097fbf4d-454d-4249-8c48-b3a32a47775d"
"<div></div>","NarrativeContent_76","8.4.8","Serious and Unexpected Adverse Reaction Reporting","SECTION 8.4.8","af6144bf-6200-4fa2-a991-388f5be3a3c5"
"<div></div>","NarrativeContent_77","8.4.9","Adverse Events of Special Interest","SECTION 8.4.9","7a0f0aef-8280-4c44-ac3b-c07cae8b8a6b"
"<div></div>","NarrativeContent_78","8.4.10","Disease-related Events or Outcomes Not Qualifying as AEs or SAEs","SECTION 8.4.10","52fe2b1b-8bd5-4ea1-b611-abc1b49b3535"
"<div></div>","NarrativeContent_79","8.5","Pregnancy and Postpartum Information","SECTION 8.5","474dcd95-fbb4-491d-ae74-62a1c3310fc9"
"<div></div>","NarrativeContent_80","8.5.1","Participants Who Become Pregnant During the Trial","SECTION 8.5.1","3b273f09-8bce-4a47-9589-8712169ae4ab"
"<div></div>","NarrativeContent_81","8.5.2","Participants Whose Partners Become Pregnant","SECTION 8.5.2","1f4e7631-c535-4ff2-840d-96942cd28cac"
"<div></div>","NarrativeContent_82","8.6","Medical Device Product Complaints for Drug/Device Combination Products","SECTION 8.6","f7066cff-80b8-47f4-b24d-d5c01f334b82"
"<div></div>","NarrativeContent_83","8.6.1","Definition of Medical Device Product Complaints","SECTION 8.6.1","8b70e200-9343-4a87-9198-1efb488afe1b"
"<div></div>","NarrativeContent_84","8.6.2","Recording of Medical Device Product Complaints","SECTION 8.6.2","b4f0f321-44b9-470f-b01b-d27a05fa43bd"
"<div></div>","NarrativeContent_85","8.6.3","Time Period and Frequency for Collecting Medical Device Product Complaints .","SECTION 8.6.3","a985225b-577c-4162-a5db-01c1ef59b197"
"<div></div>","NarrativeContent_86","8.6.4","Follow-Up of Medical Device Product Complaints","SECTION 8.6.4","54b0fc78-34f0-4d80-be9b-54c5c48dcf6d"
"<div></div>","NarrativeContent_87","8.6.5","Regulatory Reporting Requirements for Medical Device Product Complaints","SECTION 8.6.5","80162192-cdbb-42cd-bab9-0854258c8ea9"
"<div></div>","NarrativeContent_88","8.7","Pharmacokinetics","SECTION 8.7","fe15fb55-3494-4828-bd7a-9964c48d9c47"
"<div></div>","NarrativeContent_89","8.8","Genetics","SECTION 8.8","beeefd80-9d52-4b66-ac51-4febf1b6f8a7"
"<div></div>","NarrativeContent_90","8.9","Biomarkers","SECTION 8.9","5546b625-625d-441c-84c6-960b9193d9fe"
"<div></div>","NarrativeContent_91","8.1","Immunogenicity Assessments","SECTION 8.1","08478876-035d-403c-8c04-9846b44f4e8a"
"<div></div>","NarrativeContent_92","8.1.1","Medical Resource Utilisation and Health Economics","SECTION 8.1.1","71df014a-88c8-4adb-af15-68968a3e103b"
"<div></div>","NarrativeContent_93","9","STATISTICAL CONSIDERATIONS","SECTION 9","6a830360-97c1-41dd-ad9a-8d3cff40e13e"
"<div></div>","NarrativeContent_94","9.1","Analysis Sets","SECTION 9.1","a9b4e1ba-d5ff-489d-a3a4-3f42cff50692"
"<div></div>","NarrativeContent_95","9.2","Analyses Supporting Primary Objective(s)","SECTION 9.2","b8bd771a-7ba3-42eb-970b-f0ecf7f26527"
"<div></div>","NarrativeContent_96","9.2.1","Statistical Model, Hypothesis, and Method of Analysis","SECTION 9.2.1","e0027511-c165-4920-87ae-9905c88c248a"
"<div></div>","NarrativeContent_97","9.2.2","Handling of Intercurrent Events of Primary Estimand(s)","SECTION 9.2.2","ee8c72d8-98dc-47a4-8427-8fd8c6c638c5"
"<div></div>","NarrativeContent_98","9.2.3","Handling of Missing Data","SECTION 9.2.3","bb1d75f3-c515-4dfa-a793-d7f4707f7624"
"<div></div>","NarrativeContent_99","9.2.4","Sensitivity Analysis","SECTION 9.2.4","65247cc3-7fe3-432c-a20f-ef96770b315a"
"<div></div>","NarrativeContent_100","9.2.5","Supplementary Analysis","SECTION 9.2.5","e568a487-ff34-46ed-b7f1-b0351a796025"
"<div></div>","NarrativeContent_101","9.3","Analysis Supporting Secondary Objective(s)","SECTION 9.3","2a177446-7d05-45ba-b104-125b0fa25ee5"
"<div></div>","NarrativeContent_102","9.4","Analysis of Exploratory Objective(s)","SECTION 9.4","b2da7164-a422-4721-a398-6c36c2a0950d"
"<div></div>","NarrativeContent_103","9.5","Safety Analyses","SECTION 9.5","bdd63ec1-ced3-436f-97f4-2accb354abcb"
"<div></div>","NarrativeContent_104","9.6","Other Analyses","SECTION 9.6","09ef498e-869a-44e0-a004-992f913bb78b"
"<div></div>","NarrativeContent_105","9.7","Interim Analyses","SECTION 9.7","f72cc479-9e6e-46a2-9a60-555d786cf241"
"<div></div>","NarrativeContent_106","9.8","Sample Size Determination","SECTION 9.8","bee3298a-4741-42aa-9edb-09a8a37fb22c"
"<div></div>","NarrativeContent_107","9.9","Protocol Deviations","SECTION 9.9","e0187954-a58d-4dfe-9834-d5722adf2c92"
"<div></div>","NarrativeContent_108","10","GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT","SECTION 10","1194b736-2f39-4198-b226-2aa2d3fd9df7"
"<div></div>","NarrativeContent_109","10.1","Regulatory and Ethical Considerations","SECTION 10.1","a4a4636d-4b5f-4ce0-bc5d-87607323f969"
"<div></div>","NarrativeContent_110","10.2","Committees","SECTION 10.2","5f983979-c8ec-482d-8df9-bebc656bc90f"
"<div></div>","NarrativeContent_111","10.3","Informed Consent Process","SECTION 10.3","cf4eaff0-1a46-4928-95da-2586f05789ad"
"<div></div>","NarrativeContent_112","10.4","Data Protection","SECTION 10.4","67ebfa31-ce92-4cb5-b1a2-802f57622237"
"<div></div>","NarrativeContent_113","10.5","Early Site Closure or Trial Termination","SECTION 10.5","afd94120-d7fc-4092-b69d-b70ce1dacd21"
"<div></div>","NarrativeContent_114","11","GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE","SECTION 11","de518cd3-e19a-464d-a596-ef16c0a669a2"
"<div></div>","NarrativeContent_115","11.1","Quality Tolerance Limits","SECTION 11.1","99d2d15d-9f96-48ea-993b-0d2c90ced40f"
"<div></div>","NarrativeContent_116","11.2","Data Quality Assurance","SECTION 11.2","f8a64be4-2b0c-4784-967f-ac3f4844edba"
"<div></div>","NarrativeContent_117","11.3","Source Data","SECTION 11.3","12fbd73b-3230-424f-9e37-7370999df0ed"
"<div></div>","NarrativeContent_118","12","APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY","SECTION 12","8b1ed893-dc3f-4bee-bc99-7a2fd8421484"
"<div></div>","NarrativeContent_119","12.1","Further Details and Clarifications on the AE Definition","SECTION 12.1","2664909d-56c8-47ca-bbe2-73bc2057a739"
"<div></div>","NarrativeContent_120","12.2","Further Details and Clarifications on the SAE Definition","SECTION 12.2","3e94cbbb-a651-41c7-b608-9cd320039c8d"
"<div></div>","NarrativeContent_121","12.3","Severity","SECTION 12.3","8242e887-aabc-48d7-8165-fa44aaf56f70"
"<div></div>","NarrativeContent_122","12.4","Causality","SECTION 12.4","27161bd8-877a-49e1-9694-327ab40ba537"
"<div></div>","NarrativeContent_123","13","APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS","SECTION 13","81f40f6f-5cee-4376-a142-44f6eae9a5d2"
"<div></div>","NarrativeContent_124","13.1","Contraception and Pregnancy Testing","SECTION 13.1","147a1b39-96a1-4acd-a139-e42754964af3"
"<div></div>","NarrativeContent_125","13.1.1","Definitions Related to Childbearing Potential","SECTION 13.1.1","f7336d66-5bb5-4bed-95fc-14d5b45fae3d"
"<div></div>","NarrativeContent_126","13.1.2","Contraception","SECTION 13.1.2","e44f7c3a-81c8-46c7-a4f6-d809c183b360"
"<div></div>","NarrativeContent_127","13.1.3","Pregnancy Testing","SECTION 13.1.3","a79373d4-9fca-4f8e-a051-8610f290076e"
"<div></div>","NarrativeContent_128","13.2","Clinical Laboratory Tests","SECTION 13.2","c6ca58dd-88b7-448e-bd21-cc259e7c47dd"
"<div></div>","NarrativeContent_129","13.3","Country/Region-Specific Differences","SECTION 13.3","ab8ddcb3-981f-477a-bec9-ceaf86908abf"
"<div></div>","NarrativeContent_130","13.4","Prior Protocol Amendments","SECTION 13.4","10deaf43-5f2a-4ecd-8819-39bf5f60eaf3"
"<div></div>","NarrativeContent_131","14","APPENDIX: GLOSSARY OF TERMS","SECTION 14","b170a455-ef89-4617-961b-cfb0349a85f3"
"<div></div>","NarrativeContent_132","15","APPENDIX: REFERENCES","SECTION 15","d19b49ae-c902-43c0-a708-2835c34d8a8d"
